Search results for " astrazeneca"
Article
mAbs to Watch in 2016
This mAb is being developed for the treatment of psoriasis and psoriatic arthritis, and may directly compete with Novartis’ Cosentyx (secukinumab) and AstraZeneca/Valeant’s brodalumab. Brodalumab, how…
Article
Risk Assessment and Mitigation in Biopharmaceutical Manufacturing
…, associate director of quality assurance, and Paul Davis, senior manager of business resilience, at AstraZeneca Biologics to get the latest on performing risk management in biopharmaceutical manufac…
Webcast
Webinar: Building an Innovative Integrated Continuous Downstream Manufacturing Platform for the Production of Biologics
A streamlined control strategy for AstraZeneca’s development of ICB to test this implementation for 14 days of continuous end-to-end process operation at the clinical manufacturing scale will be prese…
Article
The Bullish Outlook for Biosimilars
This growth trend is set to continue, with more than 370 biologics currently in development, and pharma giants like AstraZeneca, Bristol-Myers Squibb, and Pfizer poised to have biologics represent a s…
Article
Pharma Investments Reflect Key Industry Trends
AstraZeneca: AstraZeneca announced in late 2013 that it is expanding its presence in Macclesfield, UK. The company is investing $190 million in a new plant to increase production of its blockbuster pr…
Article
Report from the 6th International HTPD Conference
Alison Tang from AstraZeneca instead highlighted the issue with pH measurement: measuring pH accurately in a high throughput fashion using a small amount of sample has always been a challenge. Indeed,…
Article
Maximum Output Starts with Optimized Upstream Processing
By Cynthia A. Challener
Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity.
Significant growth in the develo…
Article
Case Study: High Throughput mAb Purification Using Fibro
In this case study, a drug discovery lab at AstraZeneca finds that purifying antibodies with Fibro PrismA means they can screen more candidates per week with a simpler equipment setup.
Click here…
Article
Modern Manufacturing Key to More Effective Vaccines
A live attenuated intranasal FluMist vaccine from AstraZeneca’s MedImmune division, an alternative to painful sticks, is back on the US recommended list after a two-year suspension due to data indicat…
Article
Vaccine Development Faces Urgency and Challenges
Similarly, Wilson Forsyth, director of quality control at AstraZeneca (AZ) Biologics Global Operations, described a complex two-year process for shifting a vaccine quality control operation from Calif…